In this issue:
Therapeutic anticoagulation in critically ill COVID-19 patients
Therapeutic anticoagulation in non-critically ill COVID-19 patients
Immune globulin for vaccine-induced thrombocytopenia
Abelacimab for prevention of VTE
Thrombocytopenia and thromboembolism after COVID-19 vaccination
Thrombosis in patients with hypereosinophilic syndrome
Tapering/discontinuing thrombopoietin receptor agonist therapy in immune thrombocytopenia
Bevacizumab for bleeding in hereditary haemorrhagic telangiectasia
COVID-19 vaccination associated immune thrombotic thrombocytopenia
DOACs for thromboembolic events in myeloproliferative neoplasms
Anti-PF4/polyanion antibody tests after COVID-19 vaccination
DOACs in patients with obesity
Bleeding rates with damoctocog alfa pegol prophylaxis for haemophilia A
Please login below to download this issue (PDF)